Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial

Giora Weisz, Philippe Généreux, Andres Iñiguez, Aleksander Zurakowski, Michael Shechter, Karen P Alexander, Ovidiu Dressler, Anna Osmukhina, Stefan James, E Magnus Ohman, Ori Ben-Yehuda, Ramin Farzaneh-Far, Gregg W Stone, for the RIVER-PCI investigators

Summary

Background Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention.

Methods We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038.

Findings Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575–758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82–1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04).

Interpretation Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population.

Funding Gilead Sciences, Menarini.

Introduction

Percutaneous coronary intervention is one of the most common medical procedures, done in 954 000 patients in the USA in 2010.1 Despite substantial improvements in technique and technology of percutaneous coronary intervention, incomplete revascularisation is present in 17–83% of patients after the procedure (partly depending on the definition),2,4 and has been strongly associated with increased rates of repeat hospitalisation, repeat revascularisation, and mortality.3,5–16

Ranolazine, a piperazine derivative, is a late sodium-current blocker that reduces intracellular calcium overload during ischaemia.7 Ranolazine has no negative inotropic, chronotropic, or dromotropic effects and has been shown to be safe and effective for the management of patients with chronic stable angina.9–21 In a post-hoc subgroup analysis from the MERLIN-TIMI 36 trial,22 patients who presented with acute coronary syndromes with a history of angina and who were treated with percutaneous coronary intervention had lower rates of cardiovascular death, recurrent ischaemia, and the composite of cardiovascular death, myocardial infarction, or recurrent ischaemia when given ranolazine than when given placebo. In view of the high incidence of incomplete revascularisation, ischaemia, and angina after percutaneous coronary intervention,2,4,3,16,3,4 ranolazine might reduce the incidence of hospitalisation after percutaneous coronary intervention due to angina and ischaemia, and could reduce the need for repeat revascularisation. We therefore did the RIVER-PCI study to assess the use of ranolazine in patients with a history of
chronic angina who had incomplete revascularisation after percutaneous coronary intervention. We postulated that ranolazine treatment would improve the prognosis of this patient population.

**Methods**

**Study design and patients**

We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA (appendix). The design and rationale of the RIVER-PCI trial have been previously reported. The appendix provides a summary of the study design.

Eligible patients were at least 18 years old and had to meet all inclusion and exclusion criteria within 14 days after completion of percutaneous coronary intervention. Patient eligibility was determined by the investigators at each study site. Major inclusion criteria were a history of chronic angina and angiographic evidence of incomplete revascularisation after percutaneous coronary intervention. We defined chronic angina as two or more episodes of anginal pain or discomfort in the chest, jaw, shoulder, back, neck, or arm that was precipitated by exertion or emotional stress and relieved by rest or sublingual nitroglycerin, and occurred on at least 2 separate days between 30 days and 1 year before percutaneous coronary intervention. Patients could also have additional angina in the 30 days before percutaneous coronary intervention. We defined incomplete revascularisation as the presence of at least one lesion with stenosis of 50% or more in diameter (visually estimated) in a coronary artery with reference vessel diameter of 2.0 mm or more, whether in a percutaneous coronary intervention-treated target vessel or in a non-treated, non-target vessel. For patients who had undergone coronary artery bypass graft surgery, we defined incomplete revascularisation as the presence of one or more lesions with visually estimated stenosis of 50% or more in diameter in a non-bypassed epicardial vessel of 2.0 mm in diameter, or at least one stenosis (≥50%) in a bypass graft supplying an otherwise non-revascularised myocardial territory. Major exclusion criteria included any future planned revascularisation (including staged procedures), an unprotected left main coronary artery lesion with stenosis of 50% or more in diameter in a bypass graft supplying an otherwise non-revascularised myocardial territory. No other pharmaceutical treatments have been assessed systematically in patients with incomplete revascularisation after percutaneous coronary intervention. We found that, compared with placebo, ranolazine did not result in lower rates of the composite primary efficacy endpoint of ischaemia-driven revascularisation or hospitalisation without revascularisation during a median follow-up duration of 1.8 years. There were also no differences between the treatment groups in the prespecified secondary endpoints of sudden cardiac death, cardiovascular death, or myocardial infarction. Use of ranolazine was not associated with major safety issues, but did result in minor adverse reactions (eg, dizziness, constipation, and nausea), which led to discontinuation more frequently than placebo. Major adverse cardiovascular events were also more common in patients aged 75 years or older.

**Implications of all the available evidence**

Our findings show that routine use of ranolazine does not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatments could be effective in improving the prognosis of high-risk patients in this population.
treatment with ranolazine for more than 7 consecutive days within 30 days, or known hypersensitivity or intolerance to ranolazine. Patients were also excluded for concomitant use of class Ia, lc, or class III antiarrhythmic drugs (except for amiodarone), strong cytochrome P450 (CYP) 3A inhibitors, CYP3A4 or P-glycoprotein inducers, 20 mg or more of simvastatin daily, 40 mg or more of lovastatin daily, or 1000 mg or more of metformin daily. The appendix provides a complete list of all inclusion and exclusion criteria.

The ethics committee at each participating centre approved the protocol. All patients provided written informed consent.

Randomisation and masking
Patients were randomly assigned (1:1) within 14 days after the index percutaneous coronary intervention, via an interactive web-based block randomisation system (block sizes of ten), to receive either ranolazine or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation.

Procedures
For the first 7 days, patients received 500 mg oral ranolazine or placebo twice daily, after which the dose was increased to 1000 mg twice daily. If the dose increase was not tolerated, the dose could be reduced back to 500 mg or temporarily discontinued and restarted. Patients were otherwise treated with standard recommended medical treatments, including antiarrhythmic drugs (other than ranolazine), at the discretion of the investigator. Follow-up in all patients was done at 1 month and 3 months post-randomisation, and every 3 months thereafter, for at least 1 year post randomisation. To assess the results of percutaneous coronary intervention and the extent of incomplete revascularisation quantitative angiographic analysis of the entire coronary tree was done by an independent core laboratory masked to treatment assignment, as previously described.

Outcomes
The primary efficacy endpoint was time from randomisation to the first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Three key secondary efficacy endpoints were prespecified: time from randomisation to the first occurrence of sudden cardiac death, cardiovascular death, or myocardial infarction. Safety endpoints included all-cause mortality, stroke, transient ischaemic attack, hospitalisation for heart failure, and major adverse cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, or stroke. All major endpoint events, including all repeat hospitalisations, repeat coronary angiographic procedures with or without revascularisation, myocardial infarction, stroke, transient ischaemic attack, and death were adjudicated by an independent clinical events committee masked to treatment allocation. The appendix provides definitions of the major endpoints.

Statistical analysis
The trial was designed as an event-driven study. Accrual of 720 primary endpoint events was needed to provide roughly 85% power to detect a 20% reduction in relative risk in the ranolazine group compared with placebo with a two-sided log-rank test at the 5% significance level. The 20% risk reduction was a conservative estimate based on previous differences in the rates of outcomes of patients with complete and incomplete revascularisation, and the previously reported ranolazine effect in the subset of patients undergoing percutaneous coronary intervention in MERLIN. Assuming a 1 year placebo event rate of 20%, exponential time-to-event distributions, identical non-informative exponential time-to-dropout distributions with a 1 year dropout rate of 5%, a recruitment period of 1-5 years, and minimum follow-up of 1 year in all patients, we anticipated enrolling about 2600 patients. We analysed the efficacy and safety endpoints with a Cox proportional hazards model stratified by history of

Figure 1: Trial profile

2734 patients screened
83 not randomised
28 did not meet eligibility criteria
34 withdrew consent
9 outside visit window
3 lost to follow-up
1 at investigator’s discretion
1 study enrolment closed
7 for other reasons

2651 patients randomly assigned

1332 allocated to ranolazine
1239 allocated to placebo

10 excluded
7 not treated
3 because of scientific misconduct at study site

1322 included in the safety analysis set

1297 included in the safety analysis set

5 excluded
5 had no qualifying percutaneous coronary intervention

1317 included in the full analysis set

1287 included in the full analysis set

10 excluded
10 had no qualifying percutaneous coronary intervention

22 excluded
19 not treated
3 because of scientific misconduct at study site
Continuous data with the Wilcoxon rank-sum test and binary data with Pearson’s χ² test. Adverse events were coded according to the Medical Dictionary for Regulatory Activities (version 17.1), with reporting of each preferred term with 2% or more events in either treatment group.

We analysed the primary and key secondary efficacy endpoints in the full analysis set, which included all patients in whom a qualifying percutaneous coronary intervention was done before randomisation and who received at least one dose of study drug (intention-to-treat analysis). Safety analyses were done in the safety analysis set, which included all randomised patients who received at least one dose of study drug. We did analyses with SAS (versions 9.2 and 9.4).

Role of the funding source
The funders of the study had a role in study design, data collection, data analysis, and data interpretation, but not the writing of the report. GW and GWS had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
Figure 1 shows the trial profile. Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2619 (99%) patients comprised the safety analysis set and 2604 (98%) patients comprised the full analysis set (figure 1). The median duration of follow-up was 644 days (IQR 575–757) for the ranolazine group and 642 days (575–761) for the placebo group (p=0·49).

Baseline characteristics were well balanced between groups (table I). Roughly a third of patients had diabetes, a third presented with acute coronary syndrome, and more
Figure 2: Kaplan-Meier time-to-event curves for the primary efficacy endpoint

(A) Composite primary endpoint of the time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation.

(B) Time to first occurrence of ischaemia-driven revascularisation.

(C) Time to first occurrence of ischaemia-driven hospitalisation without revascularisation.

HR = hazard ratio.

than 80% had class II–IV angina within the month before study entry (table 1). Use of non-study antiplatelet and anti-ischaemic drugs was similar between groups at the time of randomisation and follow-up, except for a slightly greater use of adenosine diphosphate receptor antagonists at 12 months in the ranolazine group (appendix). The mean time from the qualifying percutaneous coronary intervention to randomisation was 6–6 days (SD 4–4) in the ranolazine group versus 6–5 days (4–4) in the placebo group (p=0·54). Table 2 shows the extent of coronary artery disease at baseline and after percutaneous coronary intervention. The mean baseline SYNTAX score was 16–9 (SD 8–3) and the mean residual score after PCI was 10–5 (7–1); both scores were balanced between groups (table 2).

The most common site-reported reasons for incomplete revascularisation were the belief that medical treatment was an accepted approach for the degree of untreated atherosclerosis, that, angiographically, any residual lesions were unlikely to be clinically significant, and that percutaneous coronary intervention would have a low likelihood of acute success (appendix).

The composite primary efficacy endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (figure 2, table 3). The incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation without revascularisation did not differ significantly between groups (table 3). The treatment effect for the primary endpoint was consistent across subgroups (figure 3). Moreover, in a Cox model, the treatment effect for the primary endpoint was similar between the 886 ranolazine patients and 852 placebo patients prescribed no or one non-study anti-ischaemic drug (β blockers, calcium-channel blockers or long-acting nitrates) at the time of randomisation (212 [24%] vs 232 [27%]; HR 0·90, 95% CI 0·75–1·09) and the 431 ranolazine patients and 435 placebo patients prescribed two to three non-study anti-ischaemic drugs (133 [31%] vs 132 [30%]; 1·04, 0·82–1·32; pInteraction 0·36).

In patients undergoing ischaemia-driven revascularisation during follow-up, about half the revascularisation procedures were performed on lesions in the originally treated vessel, whereas half were performed in untreated coronary arteries (appendix). Most of the ischaemia-driven revascularisations arose at the site of a successfully treated lesion that developed restenosis or stent thrombosis (target lesion revascularisation), or were performed on a previously present baseline lesion that qualified the patient for incomplete revascularisation; fewer revascularisation events were due to new lesions that were not previously present or were non-obstructive (diameter stenosis <50%) at the time of randomisation (appendix). Ranolazine had no significant treatment effect on the need for revascularisation of each of these three types of lesions (appendix).

The key secondary efficacy endpoints of sudden cardiac death, cardiovascular death, and myocardial
infarction occurred with similar frequency in both groups (table 3). The incidence of major adverse cardiovascular events, all-cause mortality, stroke, or hospitalisation for heart failure likewise did not differ significantly between groups; however, the incidence of adjudicated transient ischaemic attack events was higher in patients given ranolazine (table 3). Safety outcomes in the treatment groups occurred with similar frequency in several subgroups, except for major adverse cardiovascular events in very elderly patients (appendix). 401 (15%) of the 2619 patients in the safety analysis set were aged 75 years or older (n=206 in the ranolazine group and n=195 in the placebo group). In this subgroup, major adverse cardiovascular events were more frequent in patients in the ranolazine group than in those in the placebo group (HR 1.79, 95% CI 1.06–3.00; p=0.03; appendix). By contrast, the rates of major adverse cardiovascular events were similar in the 2218 (85%) patients younger than 75 years (HR 0.88, 95% CI 0.67–1.13; p=0.31). The p value for interaction between treatment group and advanced age for the outcome of major adverse cardiovascular events was 0.02. Among patients aged 75 years or older, the imbalance in major adverse cardiovascular events was driven by non-fatal events: myocardial infarction (n=26 with ranolazine vs n=18 with placebo; 1.53, 0.84–2.83; p=0.17) and stroke (n=8 vs n=4; 2.17, 0.68–8.21; p=0.02). In this subgroup, there were two cardiovascular deaths in the ranolazine group and one in the placebo group.

The median duration on study drug was slightly shorter in the ranolazine group than in the placebo group (579 days [IQR 229–674] vs 586 days [361–688]; p=0.004), and the number of patients discontinuing study drug during follow-up was higher in the ranolazine group (529 [40%] vs 463 [36%]; p=0.006). 373 (28%) patients in the ranolazine group versus 295 (23%) patients in the placebo group discontinued study drug at 12 months or earlier (p=0.01). The appendix shows detailed reasons for study drug discontinuation. We recorded discontinuation due to an adverse event in 189 (14%) of 1322 patients in the ranolazine group and 137 (11%) of 1297 patients in the placebo group (p=0.004; table 3; appendix). Dizziness, constipation, nausea, hypotension, vomiting, and vertigo were reported more often in the ranolazine group than in the placebo group (appendix). Dizziness, constipation, nausea, hypotension, vomiting, and vertigo were reported more often in the ranolazine group than in the placebo group (appendix). Dizziness, constipation, nausea, hypotension, vomiting, and vertigo were reported more often in the ranolazine group than in the placebo group (appendix).

Discussion
Our findings show that compared with placebo, ranolazine did not reduce rates of the composite primary efficacy endpoint of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. There were also no differences between the treatment groups in the prespecified major secondary efficacy endpoints of sudden cardiac death, cardiovascular death, and myocardial infarction. Ranolazine was associated with more frequent adverse events leading to early drug discontinuation, and a higher rate of non-fatal major adverse cardiovascular events in patients aged 75 years and older, than was placebo.

Previous studies2-13-16 have reported that incomplete revascularisation after percutaneous coronary intervention is associated with poor prognosis. In the ACUITY trial,2 incomplete revascularisation, as estimated by a residual SYNTAX score of more than 8, was a powerful predictor of 30 day and 1 year mortality and major adverse cardiovascular events. In the SYNTAX trial,26 a residual SYNTAX score of more than 8 was strongly associated with 5 year mortality. In the present study, the mean residual SYNTAX score after percutaneous coronary intervention was 10.5 (SD 7.1), and ischaemic events during follow-up occurred frequently, at a rate similar to that we predicted from previous studies.2-26 However, despite this degree of untreated coronary atherosclerosis, ranolazine did not reduce ischaemia-driven hospitalisation or revascularisation events during a median follow-up of 1.8 years.

There are several possible explanations why ranolazine might have been ineffective. First, despite contributing to a high residual SYNTAX score, many of the lesions left untreated after percutaneous coronary intervention might have been of little clinical consequence, consisting of relatively small vessels supplying limited myocardium. However, the ischaemic event rate was high, and nearly half of all revascularisation procedures during follow-up were performed on these untreated lesions. Moreover,

<table>
<thead>
<tr>
<th>Table 3: Efficacy and safety endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HR (95% CI)</strong></td>
</tr>
<tr>
<td><strong>Primary efficacy endpoint</strong></td>
</tr>
<tr>
<td>Ranolazine group (n=1317)</td>
</tr>
<tr>
<td>Ischaemia-driven revascularisation</td>
</tr>
<tr>
<td>Ischaemia-driven hospitalisation</td>
</tr>
<tr>
<td><strong>Secondary efficacy endpoints</strong></td>
</tr>
<tr>
<td>Sudden cardiac death</td>
</tr>
<tr>
<td>Ischaemic death</td>
</tr>
<tr>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>Q wave</td>
</tr>
<tr>
<td>Non-Q wave</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
<tr>
<td>Transient ischaemic attack</td>
</tr>
<tr>
<td>Heart failure hospitalisation</td>
</tr>
<tr>
<td>Ischaemia-related</td>
</tr>
<tr>
<td>Non-ischaemia-related</td>
</tr>
</tbody>
</table>

Data are n (%), unless otherwise indicated. HR=hazard ratio. *Without revascularisation. †n=1322 in the ranolazine group, n=1297 in the placebo group (safety analysis set).
there was no significant interaction between the residual SYNTAX score (the calculation of which incorporates lesion location and myocardium at risk) and treatment on the primary endpoint. Second, the correlation between severity of angiographic stenosis and ischaemia is known to be modest,27 and the incidence and severity of residual ischaemia in the present patient population is unknown. In the FAME 2 trial,28 the presence of untreated epicardial stenoses with a fractional flow reserve of 0·80 or less was strongly associated with the need for hospitalisation and ischaemia-driven revascularisation within 2 years. FAME 2 differs from the present study in that the untreated lesions were readily amenable to percutaneous coronary intervention, and some events in the control group could have been driven by the unmasked nature of that study. Nonetheless, the requirement for substantial myocardial ischaemia in our study might have identified patients more likely to benefit from ranolazine. However, assessment for residual ischaemia after percutaneous coronary intervention is not routine (with either fractional flow reserve or non-invasive testing). Thus, we used an anatomical definition of incomplete revascularisation based on previous studies showing that the presence of one or more lesions with stenoses of 50% or more in diameter and reference vessel diameter ≥2 mm or more maximised the sensitivity and specificity for subsequent ischaemic major adverse cardiovascular events. Third, anatomic incomplete revascularisation could represent a surrogate for atherosclerosis burden.

**Figure 3:** Subgroup analysis of the primary efficacy endpoint

<table>
<thead>
<tr>
<th>Sex</th>
<th>Number of patients</th>
<th>Number of events (%)</th>
<th>HR (95% CI)</th>
<th>HR (95% CI)</th>
<th>(P_{\text{interaction}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Ranolazine</td>
<td>1043</td>
<td>258 (25%)</td>
<td>281 (27%)</td>
<td>0·91 (0·77–1·08)</td>
</tr>
<tr>
<td>Female</td>
<td>Placebo</td>
<td>1030</td>
<td>283 (27%)</td>
<td>312 (29%)</td>
<td>1·07 (0·79–1·44)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>Ranolazine</td>
<td>799</td>
<td>191 (27%)</td>
<td>205 (29%)</td>
<td>0·94 (0·77–1·15)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>715</td>
<td>200 (28%)</td>
<td>222 (27%)</td>
<td>0·91 (0·78–1·07)</td>
</tr>
<tr>
<td>&lt;65</td>
<td>Ranolazine</td>
<td>608</td>
<td>152 (25%)</td>
<td>159 (28%)</td>
<td>0·95 (0·77–1·20)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>572</td>
<td>168 (29%)</td>
<td>185 (32%)</td>
<td>0·92 (0·78–1·07)</td>
</tr>
<tr>
<td>≥65</td>
<td>Ranolazine</td>
<td>1111</td>
<td>296 (27%)</td>
<td>320 (29%)</td>
<td>0·92 (0·78–1·07)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>1095</td>
<td>310 (28%)</td>
<td>334 (30%)</td>
<td>1·17 (0·78–1·76)</td>
</tr>
<tr>
<td>North America</td>
<td>Ranolazine</td>
<td>742</td>
<td>175 (24%)</td>
<td>190 (26%)</td>
<td>0·95 (0·77–1·17)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>742</td>
<td>180 (24%)</td>
<td>195 (26%)</td>
<td>0·94 (0·76–1·16)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Ranolazine</td>
<td>575</td>
<td>150 (30%)</td>
<td>174 (32%)</td>
<td>0·90 (0·74–1·08)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>545</td>
<td>137 (25%)</td>
<td>152 (29%)</td>
<td>1·04 (0·82–1·32)</td>
</tr>
<tr>
<td>PCI for ACS indication</td>
<td>Ranolazine</td>
<td>874</td>
<td>205 (23%)</td>
<td>229 (27%)</td>
<td>0·91 (0·76–1·10)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>857</td>
<td>211 (24%)</td>
<td>235 (28%)</td>
<td>1·02 (0·79–1·33)</td>
</tr>
<tr>
<td>Invasive device</td>
<td>Ranolazine</td>
<td>443</td>
<td>140 (32%)</td>
<td>163 (35%)</td>
<td>0·92 (0·78–1·12)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>430</td>
<td>137 (30%)</td>
<td>160 (32%)</td>
<td>0·93 (0·76–1·15)</td>
</tr>
<tr>
<td>Residual SYNTAX score</td>
<td>Ranolazine</td>
<td>689</td>
<td>174 (25%)</td>
<td>186 (28%)</td>
<td>0·82 (0·64–1·05)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>674</td>
<td>168 (26%)</td>
<td>188 (29%)</td>
<td>0·97 (0·77–1·21)</td>
</tr>
<tr>
<td>&lt;9 (median)</td>
<td>Ranolazine</td>
<td>499</td>
<td>119 (24%)</td>
<td>139 (28%)</td>
<td>0·99 (0·73–1·35)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>493</td>
<td>125 (24%)</td>
<td>142 (28%)</td>
<td>0·94 (0·79–1·2)</td>
</tr>
<tr>
<td>≥9 (median)</td>
<td>Ranolazine</td>
<td>555</td>
<td>135 (24%)</td>
<td>146 (26%)</td>
<td>0·90 (0·76–1·1)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>555</td>
<td>139 (25%)</td>
<td>156 (28%)</td>
<td>0·95 (0·74–1·24)</td>
</tr>
<tr>
<td>PCI device</td>
<td>Ranolazine</td>
<td>319</td>
<td>82 (26%)</td>
<td>87 (26%)</td>
<td>0·90 (0·76–1·06)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>311</td>
<td>85 (26%)</td>
<td>90 (27%)</td>
<td>1·20 (0·86–1·68)</td>
</tr>
<tr>
<td>Drug-eluting stent</td>
<td>Ranolazine</td>
<td>961</td>
<td>257 (27%)</td>
<td>266 (29%)</td>
<td>0·90 (0·76–1·06)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>914</td>
<td>262 (27%)</td>
<td>271 (30%)</td>
<td>1·20 (0·86–1·68)</td>
</tr>
<tr>
<td>Total occlusion</td>
<td>Ranolazine</td>
<td>843</td>
<td>215 (25%)</td>
<td>225 (27%)</td>
<td>0·94 (0·78–1·13)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>827</td>
<td>219 (25%)</td>
<td>233 (27%)</td>
<td>0·95 (0·74–1·24)</td>
</tr>
<tr>
<td>Previous CABG</td>
<td>Ranolazine</td>
<td>441</td>
<td>120 (27%)</td>
<td>138 (30%)</td>
<td>0·90 (0·76–1·06)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>423</td>
<td>117 (24%)</td>
<td>136 (30%)</td>
<td>1·20 (0·86–1·68)</td>
</tr>
<tr>
<td>Baseline BNP (ng/L)</td>
<td>Ranolazine</td>
<td>1108</td>
<td>269 (24%)</td>
<td>300 (27%)</td>
<td>0·90 (0·71–1·13)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>1091</td>
<td>275 (25%)</td>
<td>307 (28%)</td>
<td>0·95 (0·76–1·21)</td>
</tr>
<tr>
<td>≥80</td>
<td>Ranolazine</td>
<td>545</td>
<td>141 (26%)</td>
<td>155 (29%)</td>
<td>0·90 (0·71–1·13)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>524</td>
<td>145 (26%)</td>
<td>159 (28%)</td>
<td>0·95 (0·76–1·16)</td>
</tr>
<tr>
<td>&gt;80</td>
<td>Ranolazine</td>
<td>691</td>
<td>180 (26%)</td>
<td>201 (28%)</td>
<td>0·82 (0·71–1·08)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>711</td>
<td>184 (27%)</td>
<td>206 (30%)</td>
<td>1·16 (0·81–1·66)</td>
</tr>
<tr>
<td>Baseline LVEF (%)</td>
<td>Ranolazine</td>
<td>651</td>
<td>171 (26%)</td>
<td>190 (30%)</td>
<td>0·87 (0·71–1·08)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>637</td>
<td>180 (27%)</td>
<td>199 (31%)</td>
<td>1·16 (0·81–1·66)</td>
</tr>
<tr>
<td>≥50</td>
<td>Ranolazine</td>
<td>275</td>
<td>64 (28%)</td>
<td>68 (29%)</td>
<td>0·95 (0·82–1·10)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>295</td>
<td>73 (25%)</td>
<td>81 (29%)</td>
<td>0·95 (0·82–1·10)</td>
</tr>
<tr>
<td>&lt;50</td>
<td>Ranolazine</td>
<td>1317</td>
<td>345 (26%)</td>
<td>364 (28%)</td>
<td>0·95 (0·82–1·10)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>1287</td>
<td>349 (26%)</td>
<td>376 (29%)</td>
<td>0·95 (0·82–1·10)</td>
</tr>
</tbody>
</table>
ISCHAEMIA. Unlike other drugs, the anti-ischaemic reducing intracellular calcium overload during underpowered subgroups. In this regard, our findings differ from those of the PROSPECT study, in which nearly half the follow-up events after percutaneous coronary intervention arose from angiographically mild lesions that rapidly progressed. This difference might be because PROSPECT included only patients with acute coronary syndromes (in whom the incidence of untreated vulnerable plaques is higher than in patients with stable coronary artery disease), and fewer patients had incomplete revascularisation. Additionally, a high proportion of patients in the present study were treated with statins, dual antiplatelet treatment, and other guideline-directed medical treatments, which could have mitigated the effect of untreated atherosclerosis on future events. However, neither these drugs nor ranolazine would be likely to reduce ischaemia-driven target lesion revascularisation due to restenosis or stent thrombosis, which contributed to about 40% of ischaemia-driven revascularisation events. Finally, ranolazine has a unique anti-ischaemic mechanism that distinguishes it from other drugs. Ischaemia increases intracellular sodium concentrations, which, by increasing ion flux through the membrane-based sodium–calcium exchanger, leads to intracellular calcium overload, with resultant abnormalities in ventricular repolarisation and relaxation. Ranolazine selectively inhibits the late sodium current, thereby reducing intracellular calcium overload during ischaemia. Unlike other drugs, the anti-ischaemic effects of ranolazine are not dependent on reductions in heart rate or blood pressure, and ranolazine does not affect the rate-pressure product at maximum exercise—a measure of myocardial work. Thus, ranolazine does not prevent the development of ischaemia, but rather diminishes its severity. A different anti-ischaemic drug might have been more effective for the application tested.

Additional insights from the present study results can be gained by considering the findings of the MERLIN-TIMI 36 trial, in which the rates of ischaemia-related hospitalisation and revascularisation were also similar in patients with acute coronary syndrome given ranolazine or placebo. However, in a modest-sized (n=914) subgroup of patients from MERLIN with previous angina who were treated with percutaneous coronary intervention, ranolazine reduced the risk of recurrent ischaemia (HR 0·69, 95% CI 0·52–0·92; p=0·01) and cardiovascular death (0·39, 95% CI 0·16–0·91; p=0·03), a finding that partly prompted the present study. These hypothesis-generating results were not validated in the present larger, adequately powered trial, emphasising once again the caution needed in interpretation of post-hoc, underpowered subgroups.

Use of ranolazine in patients who had undergone percutaneous coronary intervention in our study was not associated with major safety concerns. The rates of all-cause mortality, myocardial infarction, stroke, hospitalisation due to heart failure, and major adverse cardiovascular events (the composite of cardiovascular mortality, myocardial infarction, or stroke) were similar between the ranolazine and placebo groups. We recorded an excess in adjudicated transient ischaemic attack events in patients given ranolazine, but the number of such events was small, and the absence of an increase in stroke argues against a major thromboembolic mechanism. The incidence of stroke and transient ischaemic attack has not been reported in previous ranolazine trials. In patients aged 75 years or older in the present study, the rate of major adverse cardiovascular events during follow-up was increased in patients in the ranolazine group compared with those in the placebo group. Statistical adjustment for testing of multiple subgroups was not done, and this finding might represent type I error. However, in previous chronic angina studies, in patients aged 75 years or older treated with ranolazine (n=114), a higher incidence of adverse events, serious adverse events, and drug discontinuations because of adverse events were noted in patients given ranolazine than in those given placebo.

Our study has several limitations. First, hypertension was slightly more prevalent in the placebo group and previous percutaneous coronary intervention was slightly more prevalent in the ranolazine group. These differences were small and probably did not affect the results. Second, background antianginal drug use (other than ranolazine) was left to local standards, and most patients were receiving one or two additional anti-ischaemia drugs (β blockers, calcium-channel blockers, or nitrates). Whether the results would have been different had control patients been naive to antianginal drugs is unknown. However, no interaction was shown between the number of prescribed non-study anti-ischaemic drugs and treatment effect on the recurrent ischaemia-related primary endpoint. Third, detailed data for the number and configuration of stents were not collected, although they were likely to be balanced by randomisation. Moreover, baseline and residual data for SYNTAX score were similar between the groups, and ranolazine did not affect recurrent ischaemic events arising either from treated or untreated coronary segments. Fourth, 40% of the ranolazine patients and 36% of the placebo patients discontinued study drug before the end of the follow-up duration, and the median duration of ranolazine use was shorter, which could have biased the results toward the null. However, the median duration of treatment with ranolazine was 379 days (1–6 years), and it is unlikely that absence of treatment is entirely responsible for the nearly identical course of recurrent events...
Articles

recorded, especially in the first year of follow-up. Fifth, we chose the primary endpoint of time to first occurrence of ischaemia-driven revascularisation or hospitalisation because ranolazine was not expected to have an effect on the hard endpoints of death or myocardial infarction. These relatively soft endpoints are subjective and might vary on the basis of patient and physician tolerance for angina, symptom presentation, and interpretation. Nonetheless, the chosen endpoints were robust, because the criteria for their diagnosis were detailed and prespecified, and required masked adjudication by a clinical events committee based on review of original source documents. That the trial was placebo-controlled also denotes that any uncertainty or bias in event adjudication would be applied equally to both study groups.

In summary, routine treatment with ranolazine did not reduce the rate of ischemia-driven revascularisation or hospitalisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention.

Contributors
GW, GWS, and OB-Y designed the study. RF-F, KPA, SJ, and EMO were members of the steering committee and contributed to the implementation of the study. OD and AO did the statistical design and analysis. PG did the angiographic analysis. KPA, PG, SJ, AI, AZ, MS, and EMO participated in patient enrollment and follow-up. GW and GWS had full access to the data, wrote the manuscript, and accept responsibility for the integrity of the study. All other authors critically reviewed the manuscript for revision. All authors have approved the final manuscript and agree with its content and conclusions.

Declaration of interests
GW serves on the medical advisory boards of AngioSlide, AstraZeneca, Galore, Corinthus, Medtronic, Medvisor, and M1 Medical Incentives, and receives institutional research grants from AngioSlide and Corinthus. PG has received consulting fees from Abbott Vascular. Cardiovascular Systems, and Edwards Lifesciences; an institutional research grant from Boston Scientific; and is an employee of Cardiovascular Research Foundation, which received a grant from Gilead Sciences for study management. OB-Y is a former employee of Gilead Sciences and is a currently employee of the Cardiovascular Research Foundation, which received a grant from Gilead Sciences for study management. KPA has received consulting fees and research grants from Gilead Sciences, research grants from Sanofi Aventis and Regeneron, and consulting fees from CyRx. EMO has received research grants from Gilead Sciences and Jansen Pharmaceuticals, and consulting fees from AstraZeneca, Merck, Eli-Lilly–Daichi Sankyo, and Boehringer Ingelheim. AO is an employee of Gilead Sciences. OB-Y and RF-F are former employees of Gilead Sciences. SJ has received institutional research grants from Gilead Sciences. GWS has served as a consultant for Resa, Boston Scientific, AstraZeneca, Eli Lilly–Daichi Sankyo, InspireMD, Volcano, InfracRoadx, Cardiovascular Systems, and Matrizyme. All other declare no competing interests.

Acknowledgments
The study was sponsored and funded by Gilead Sciences and the Menarini Group.

References
17 Belardelli L, Shroyer JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92: 06–14.


